Taken together, these findings suggest that FGF-23 exerts a pro-metastatic effect in osteosarcoma through ERK-, p38-, and JNK-mediated regulation of the miR-4463/LOXL2 axis (Fig. 6). The gene discussed is LOXL2; the disease is osteosarcoma.